Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.

The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that ...

Medtronic (NYSE:MDT) announced an agreement to acquire CathWorks, aiming to add AI-powered coronary artery disease tools to ...

The US FDA has approved Medtronic’s 780G for use with rapid-acting insulin and with Abbott’s type 2 diabetes-specific sensor.

Real-world data demonstrate that the MiniMed 780G system effectively controls glucose levels in users who do not administer bolus insulin.

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...

Mealtimes are one of the biggest challenges for people living with type 1 diabetes and frequently linked to diabetes distress. 1,2 The constant need for decision-making and mental load around ...

A second randomized controlled trial sponsored by JDRF also demonstrates superiority of automated insulin pump as first-in-line therapy for children with type 1 diabetes DUBLIN and BERLIN, Feb. 24, ...

DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...